PMH21 PSORIASIS AND DEPRESSIVE SYMPTOMATOLOGY: SPANISH RESULTS  by Taïeb, C et al.
696 Abstracts
changes in triglycerides in olanzapine-treated women 
(n = 32) versus ziprasidone-treated women (n = 44) trend-
ing toward signiﬁcance (p = 0.09). CONCLUSIONS: In
a six-week trial, men treated with olanzapine experienced
an increase in CHD risk that was signiﬁcant versus a
decrease in men treated with ziprasidone, while changes
in risk did not differ signiﬁcantly between olanzapine-
and ziprasidone-treated women. These results paralleled
changes in lipid proﬁle. Investigation is warranted into
effects of long-term treatment with atypical antipsy-
chotics on risk of CHD.
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CLIENT AND STAFF INVOLVEMENT IN FORMAT
DESIGN OF A HEALTH-RELATED QUALITY OF
LIFE SURVEY FOR INDIVIDUALS WITH
SCHIZOPHRENIA,THE SCHIZOPHRENIA
OUTCOMES ASSESSMENT PROJECT (SOAP)
SURVEY
Barr JT, Schumacher GE, Ohman SM, Quimby CM
Northeastern University, Boston, MA, USA
OBJECTIVES: Since end-users of survey may have design
format preferences that are undetected by survey devel-
oper/administrators, we elicited client and staff input and
preferences for three survey formats of a 51-item health-
related quality of life survey for community-residing indi-
viduals with schizophrenia. METHODS: Using cognitive
interviews and visual analogue preference ratings (0–100
scale), we sought qualitative and quantitative input from
29 community-residing clients with schizophrenia and 33
staff members at four sites concerning their preferences
for three formats of the 51-item Schizophrenia Outcomes
Assessment Project (SOAP-51) Survey: a 6-page booklet
with responses horizontally listed below each item, a 
4-page version with responses to the right of each item,
and a compressed 2-page version of the former. Survey
formats were presented in randomized order. Staff was
also asked their preference for four versus ﬁve-response
format. Clients were individually interviewed in 15–20
minutes sessions; staff had individual (20–30 minutes) or
group (45–60 minute) sessions. RESULTS: Clients pre-
ferred the booklet and 4-page format over the 2-page
version; respective VAS values of 70.1, 68.9, and 47.0 
(p = 0.012). Qualitatively, clients indicated that the 2-
page was too compressed and that the 4-page format
made it easier to link the response to the question. Staff
preferred 4 responses to 5 (84.0 versus 46.1, p < 0.0001)
because they perceived little distinction between two of
the ﬁve response levels. Staff had a preference trend
toward the 4-page format over the booklet or 2-page
(68.6, 58.6, and 58.9 respectively, p = 0.22). When asked
their ﬁrst choice, 47% of staff indicated 4-page; 34%, 2-
page; and 19%, booklet. CONCLUSIONS: Clients pre-
ferred booklet and 4-page formats; staff preferred 4-page
and 2-page formats. Based on this input, we have selected
the 4-page format, the common preference of both
groups. Survey developers should incorporate end-users
to provide insight into format preferences and cognitive
processing.
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TREATMENT WITH PSYCHOSTIMULANTS IS
ASSOCIATED WITH DECREASED RATES OF
SUBSTANCE ABUSE AND IMPROVED SCHOOL
OUTCOMES AMONG CHILDREN WITH AD/HD
Katusic SK, Barbaresi WJ, Colligan RC,Weaver AL,
Mrazek DA, Jacobsen SJ
Mayo Clinic, Rochester, MN, USA
OBJECTIVES: To study the long-term impact of psy-
chostimulant treatment on substance abuse and school
outcomes in a population-based cohort of AD/HD cases.
METHODS: Subjects included 282 AD/HD research
identiﬁed cases treated with psychostimulant medication
and 81 AD/HD cases that were never treated with 
psychostimulants. These subjects are subsets of the 363
research identiﬁed cases from a population-based birth
cohort, born in Rochester, MN 1976–1992 who
remained in Rochester after age 5 (N = 5,718). All 363
cases were followed from age 5 until emigration, death,
school graduation, drop out. Among 282 treated with
stimulants, 85% (N = 239) of cases were treated with
methylphenidate. Data on type of psychostimulant,
dosage prescribed (Methylphenidate Equivalent Units),
start/stop dates were collected from medical and school
records. The same resources were retrospectively and lon-
gitudinally examined for the documentation of substance
abuse and school outcomes. Associations between 
psychostimulant treatment and outcomes were evaluated
using general linear and logistic regression models.
RESULTS: Of the AD/HD cases treated with stimulants,
16.3% had documented substance abuse compared to
23.5% cases not treated (OR = 0.6; 95% CI = 0.3–1.2;
p = 0.14). Cases treated at an earlier age were less likely
to have documented substance abuse (p = 0.025) as well
as those treated for a longer duration (p = 0.17). Cases
with higher average daily psychostimulant dosage had
higher reading scores (r = 0.14, p = 0.025). Cases treated
with psychostimulants were absent signiﬁcantly less than
those who were not treated (p = 0.024). Furthermore,
cases treated longer were absent less (r = -0.18, p =
0.003). CONCLUSIONS: Our large, longitudinal, popu-
lation-based, study demonstrates that psychostimulant
treatment is associated with decreased substance abuse
and improved school outcomes among AD/HD cases.
Our study conﬁrms the positive impact and importance
of long-term treatment with psychostimulants and reﬂects
an improvement in the lives of children with AD/HD.
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